Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED4D Molecular Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$2.18 | $0.22 | -$0.74 |
| Q2 2024 | 2 | -$2.02 | $0.20 | -$0.68 |
| Q3 2024 | 2 | -$1.99 | $0.20 | -$0.68 |
| Q4 2024 | 7 | -$1.13 | -$0.61 | -$0.84 |
| Q1 2025 | 2 | -$2.41 | $0.24 | -$0.82 |
| Q2 2025 | 1 | -$2.60 | $0.26 | -$0.88 |
| Q3 2025 | 1 | -$2.75 | $0.28 | -$0.93 |
| Q4 2025 | 1 | -$2.76 | $0.28 | -$0.94 |
4D Molecular Therapeutics, Inc. Earnings Date And Information
4D Molecular Therapeutics, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.79 earnings per share for the quarter, missing analysts' consensus estimates of $-0.67 by $0.12. The company had revenue of 3,000 for the quarter and had revenue of 20.72 M for the year. 4D Molecular Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.58 diluted earnings per share) and currently has a price-to-earnings ratio of -2.25. 4D Molecular Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
4D Molecular Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.67 | -$0.79 | -0.12 | $1.62 M | $3,000 |
| 08/08/2024 | Q2 2024 | -$0.72 | -$0.63 | 0.09 | $1.27 M | $5,000 |
| 05/09/2024 | Q1 2024 | -$0.73 | -$0.66 | 0.07 | $28,000 | |
| 02/29/2024 | Q4 2023 | -$0.68 | -$0.83 | -0.15 | $-19,000 | |
| 11/09/2023 | Q3 2023 | -$0.67 | -$0.24 | 0.43 | $848,333 | $20.20 M |
| 08/09/2023 | Q2 2023 | -$0.77 | -$0.77 | 0 | $1.29 M | $239,000 |
| 05/10/2023 | Q1 2023 | -$0.83 | $298,000 | |||
| 03/15/2023 | Q4 2022 | -$0.75 | -$0.84 | -0.09 | $1.25 M | |
| 11/08/2022 | Q3 2022 | -$0.85 | -$0.74 | 0.11 | $856,000 | $500,000 |
| 08/11/2022 | Q2 2022 | -$0.78 | -$0.85 | -0.07 | $758,333 | $162,000 |
| 05/12/2022 | Q1 2022 | -$0.73 | -$0.81 | -0.08 | $1.22 M | |
| 03/28/2022 | Q4 2021 | -$0.82 | -$0.93 | -0.11 | $92,000 | |
| 11/10/2021 | Q3 2021 | -$0.83 | -$0.82 | 0.01 | $587,500 | $1.37 M |
| 08/12/2021 | Q2 2021 | -$0.71 | -$0.28 | 0.43 | $562,500 | $14.58 M |
| 05/13/2021 | Q1 2021 | -$1.10 | -$0.61 | 0.49 | $2.00 M | |
| 03/25/2021 | Q4 2020 | -$0.66 | -$0.77 | -0.11 | $-977,000 | |
| 09/29/2020 | Q3 2020 | -$0.36 | $7.42 M | |||
| 06/29/2020 | Q2 2020 | -$1.02 | $3.63 M | |||
| 03/30/2020 | Q1 2020 | -$0.89 | $3.54 M | |||
| 12/30/2019 | Q4 2019 | -$1.09 | $2.03 M |
4D Molecular Therapeutics, Inc. Earnings: FAQ's
When is 4D Molecular Therapeutics, Inc.'s earnings date?
4D Molecular Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
How can I listen to 4D Molecular Therapeutics, Inc.'s earnings conference
call?
The conference call for 4D Molecular Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read 4D Molecular Therapeutics, Inc.'s conference call transcript?
The conference call transcript for 4D Molecular Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does 4D Molecular Therapeutics, Inc. generate each year?
4D Molecular Therapeutics, Inc. (:FDMT) has a recorded annual revenue of $20.72 M.
How much profit does 4D Molecular Therapeutics, Inc. generate each year?
4D Molecular Therapeutics, Inc. (:FDMT) has a recorded net income of $20.72 M. 4D Molecular Therapeutics, Inc. has generated $-2.58 earnings per share over the last four quarters.
What is 4D Molecular Therapeutics, Inc.'s price-to-earnings ratio?
4D Molecular Therapeutics, Inc. (:FDMT) has a price-to-earnings ratio of -2.25 and price/earnings-to-growth ratio is 0.1.